BIGNOPE
Ko-fi

Recalls affecting Arizona

Data last updated: September 6, 2026 at 11:49 PM UTC

16,792 recalls found

Just announced

Straight from FDA press releases — not yet formally classified or risk-graded
Wording
Class IIILow risk
FoodRecalled October 27, 2025

Multivitamin with Fluoride Chewable Tablets Grape Flavor Rx NDC 75826-169-10 0.25 mg 100 TABLETS UPC 3 15826 16910 2; NDC 75826-171-10 1mg 100 TABLETS UPC 3 15826 17110 5 Manufactured by: WINDER LABORATORIES LLC Winder, GA 30680

Weaker than it should be. During an FDA inspection it was discovered that the product was weaker than it should be for Vitamin D.

Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
H-0569-2026
Lot/product code:
Lot 1692303 SN: 138909557498 EXP: 2025-10-26 & Lot 1692304 SN 131163901709 EXP: 2025-10-26; LOT 1712301 SN: 163590222021 EXP: 2025-11-14
Recalling firm:
Winder Laboratories, LLC
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 20, 2025

Klarity-C Drops (Cyclosporine) 0.1%, Preservative-Free Sterile Ophthalmic Emulsion, This is a compounded drug, Office Use Only, 5.5 mL bottle, Rx only, Mfg by: Imprimis NJOF, LLC, 1705 Route 46 West, Ledgewood, NJ 07852, NDC 71384-514-05

Weaker than it should be Drug

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0157-2026
Lot/product code:
Lot #:25JAN029, exp. date 07Nov2025; 25JAN042, exp. date 14Nov2025; 25JAN054, exp. date 21Nov2025; 25MAR021, exp. date 07Dec2025; 25APR017, exp. date 04Jan2026, 25APR025, exp. date 05Jan2026; 25MAY032, exp. date 31Jan2026; 25MAY055, exp. date 12Mar2026; 25MAY057, exp. date 14Mar2026; 25MAY073, exp. date 21Mar2026
Recalling firm:
Imprimis NJOF, LLC
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 10, 2025

Fesoterodine Fumarate, Extended-release Tablets, 4 mg, 30-count bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-175-30

Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0156-2026
Lot/product code:
Lot # 2405006633, Exp Date: 03/31/2026
Recalling firm:
Alembic Pharmaceuticals Limited
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 10, 2025

Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91

Failed Impurities/Degradation Specifications: not meeting quality requirements for impurity IP-C.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0142-2026
Lot/product code:
Lot #: 550172201, Exp. Date JAN-26; 550184801, Exp. Date MAR-26; 550204001, Exp. Date JUL-26
Recalling firm:
Endo USA, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 10, 2025

Everolimus tablets 10 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-128-91

Failed Impurities/Degradation Specifications: not meeting quality requirements for impurity IP-C.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0141-2026
Lot/product code:
Lot #: 550162801, Exp. Date NOV-25; 550169801, Exp. Date JAN-26
Recalling firm:
Endo USA, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 10, 2025

Everolimus tablets 5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-125-91

Failed Impurities/Degradation Specifications: not meeting quality requirements for impurity IP-C.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0139-2026
Lot/product code:
Lot #: 550184901, 550185001, Exp. Date MAR-26; 550189901, 550190001, Exp. Date APR-26 550203901, 550205601, Exp. Date Jul-26
Recalling firm:
Endo USA, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 10, 2025

Everolimus tablets 7.5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-127-91

Failed Impurities/Degradation Specifications: not meeting quality requirements for impurity IP-C.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0140-2026
Lot/product code:
Lot #: 550167301, 550167401, Exp. Date NOV-25; 550185101, Exp. Date MAR-26; 550205701, Exp. Date JUL-26
Recalling firm:
Endo USA, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 9, 2025

Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL Syringe, STAQ Pharma Inc., 14135 E 42nd Ave, Denver, Colorado, NDC 73177-0104-05.

Labeling: Incorrect or Missing Lot and/or Exp Date

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0023-2026
Lot/product code:
Lot #: 25104595A, Expiry: 27DEC2025.
Recalling firm:
STAQ Pharma, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 9, 2025

Ketamine Hydrochloride, 50mg/5 mL (10mg/mL), Injection for IV use, 50 mL syringe, STAQ Pharma Inc., 14135 E 42nd Ave, Denver, Colorado, NDC 73177-0156-02.

Labeling: Incorrect or Missing Lot and/or Exp Date

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0024-2026
Lot/product code:
Lot #: 25156673A, Expiry: 02FEB2026.
Recalling firm:
STAQ Pharma, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled October 9, 2025

FentaNYL Citrate PF, 500mcg/50 mL (10mcg/mL) in NACL, Injection for IV use, 50 mL syringe, STAQ Pharma Inc., 14135 E 42nd Ave, Denver, Colorado, NDC 73177-0102-05.

Labeling: Incorrect or Missing Lot and/or Exp Date

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0025-2026
Lot/product code:
Lot: 25102464B, Expiry: 26NOV2025; 25102370A, Expiry: 20OCT2025; 25102369A, Expiry: 19OCT2025.
Recalling firm:
STAQ Pharma, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
FoodRecalled September 23, 2025

OptiWize Health OptiWize Collagen Plus 320 count bottle; White bottle with black lid.

The firm initiated a voluntary recall after NSF testing showed that labeled ingredient quantities did not align with analytical test results, manganese level was below label quantity.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
H-0442-2026
Lot/product code:
OHB25230
Recalling firm:
Optiwize Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled September 12, 2025

Cetirizine Hydrochloride Tablets USP 10 mg, 100 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-10.

Tablet/Capsules Imprinted with Wrong ID

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0032-2026
Lot/product code:
Lot # PY925014A; Exp. 1/31/2028
Recalling firm:
JB Chemicals and Pharmaceuticals Ltd
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled September 12, 2025

Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50

Tablet/Capsules Imprinted with Wrong ID

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0033-2026
Lot/product code:
Lot # PY925014, PY925013, Exp. 1/31/2028
Recalling firm:
JB Chemicals and Pharmaceuticals Ltd
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled September 5, 2025

Everolimus tablets 5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977, NDC 49884-125-91

Failed Impurities/Degradation Specifications: not meeting quality requirements for impurity IP-C.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0026-2026
Lot/product code:
Lot #: 550172301, Exp. Date January 2026
Recalling firm:
Endo USA, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 28, 2025

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 20 mg, 100 Capsules, Rx only, Manufactured by: Granules Pharmaceuticals Inc., Chantilly, VA 20151, NDC 70010-032-01

Failed Impurities/Degradation Specifications:

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0672-2025
Lot/product code:
Lot#: GPC250179A, Exp Date: 06-22-2027
Recalling firm:
Granules Pharmaceuticals Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 28, 2025

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 15 mg, 100 Capsules, Rx only, Manufactured by: Granules Pharmaceuticals Inc., Chantilly, VA 20151, NDC 70010-031-01

Failed Impurities/Degradation Specifications:

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0671-2025
Lot/product code:
Lot#: GPC250178A, Exp Date: 06-22-2027
Recalling firm:
Granules Pharmaceuticals Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 28, 2025

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 30 mg, 100 Capsules, Rx only, Manufactured by: Granules Pharmaceuticals Inc., Chantilly, VA 20151, NDC 70010-034-01

Failed Impurities/Degradation Specifications:

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0673-2025
Lot/product code:
Lot#: GPC250181A, Exp Date: 06-19-2027
Recalling firm:
Granules Pharmaceuticals Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 28, 2025

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 100 Capsules, Rx only, Manufactured by: Granules Pharmaceuticals Inc., Chantilly, VA 20151, NDC 70010-029-01

Failed Impurities/Degradation Specifications:

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0669-2025
Lot/product code:
Lot#: GPC250158A, Exp Date: 06-22-2027
Recalling firm:
Granules Pharmaceuticals Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 28, 2025

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate, Extended-Release Capsules, (Mixed Salts of a Single Entity Amphetamine Product), 10 mg, 100 Capsules, Rx only, Manufactured by: Granules Pharmaceuticals Inc., Chantilly, VA 20151, NDC 70010-030-01

Failed Impurities/Degradation Specifications:

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0670-2025
Lot/product code:
lot#: GPC250159A, Exp Date: 06-22-2027
Recalling firm:
Granules Pharmaceuticals Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 25, 2025

TopCare Health 70% Isopropyl Alcohol, NET WT 5.5 OZ (156 g) per can, Distributed By The KROGER CO., Cincinnati, Ohio 45202. NDC: 36800-589-14

Cross Contamination with Other Products.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0661-2025
Lot/product code:
Lot 0662036; Exp Date 06/19/2027
Recalling firm:
Consumer Product Partners, LLC
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 25, 2025

Kroger 70% Isopropyl Alcohol, NET WT 5.5 OZ (156 g) per can, Distributed By The KROGER CO., Cincinnati, Ohio 45202. NDC: 30142-810-14

Cross Contamination with Other Products.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0660-2025
Lot/product code:
Lot 0662036; Exp. Date 06/19/2027
Recalling firm:
Consumer Product Partners, LLC
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 19, 2025

READYPREP PVP, Povidone-Iodine 10% Solution, Topical Antiseptic, Not Sterile, 1 Gallon (3.78 L) per bottle, Manufactured in USA by Medline Industries, LP., Three Lakes Drive, Northfield, IL 60093, NDC 53329-939-25

Weaker than it should be drug

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0674-2025
Lot/product code:
Lot # 24EJA180, Exp 06/01/2027
Recalling firm:
Medline Industries, LP
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled August 5, 2025

Sensodyne PRONAMEL (Potassium nitrate 5%, Sodium fluoride 0.25%) Active SHIELD Toothpaste for Sensitive Teeth, Fresh Mint, Net WT 3.4OZ (96.4g) Tube, 6 tubes x 2 inners, per case, Distributed by GSK Consumer Healthcare, Warren, NJ 07059. UPC 3 10158 35691 2

Labeling: Label Mix-up: The outer carton is labelled Fresh Mint. The tube is labelled Cool Mint/Whitening. The toothpaste inside the tube is Fresh Mint as indicated on the outer carton

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0592-2025
Lot/product code:
Lot # for Case: 5058RB, Exp. date: 08/31/2027 Lot # for Carton and Tube: NJ2A, Exp 08/31/2027
Recalling firm:
Haleon US Holdings LLC
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled July 24, 2025

Albuterol Sulfate, Inhalation Aerosol, 90 mcg, 200 metered Inhalations, NET CONTENT 6.7 g, Manufactured by: Cipla Ltd, Indore, SEZ, Pithampur, India; Manufactured for: Cipla USA, Inc. 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-142-60.

Failed Stability Specifications: not meeting quality requirements results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0593-2025
Lot/product code:
Lot#: 4IB0519, Exp. 04/30/2026
Recalling firm:
Cipla USA, Inc.
View official FDA record (opens in a new tab)
Class IIILow risk
DrugRecalled July 9, 2025

Fluorescein 2% Ophth, 3 ML, Boothwyn Pharmacy, 800-476-7496

Weaker than it should be Drug

ALL 50 STATES
Full report

A low-risk recall. This product is unlikely to cause any health problems, but it still doesn't meet FDA rules.

Recall #:
D-0607-2025
Lot/product code:
06092025@23 BUD 09/09/2025
Recalling firm:
Boothwyn Pharmacy LLC
View official FDA record (opens in a new tab)